Home  »  Industry   »  Here is why Brainstorm Cell Therapeutics Inc. (BCL...

Here is why Brainstorm Cell Therapeutics Inc. (BCLI) stock volatility recorded over the last month was 13.18%

For the readers interested in the stock health of Brainstorm Cell Therapeutics Inc. (BCLI). It is currently valued at $1.95. When the transactions were called off in the previous session, Stock hit the highs of $1.95, after setting-off with the price of $1.53. Company’s stock value dipped to $1.53 during the trading on the day. When the trading was stopped its value was $1.50.Recently in News on November 17, 2022, BCLI: Receives a Refusal to File Letter from the FDA for NurOwn® BLA…. By David Bautz, PhD. You can read further details here

Brainstorm Cell Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $4.7000 on 08/15/22, with the lowest value was $1.0854 for the same time period, recorded on 11/10/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Brainstorm Cell Therapeutics Inc. (BCLI) full year performance was -30.60%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Brainstorm Cell Therapeutics Inc. shares are logging -58.51% during the 52-week period from high price, and 79.66% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.09 and $4.70.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 555312 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Brainstorm Cell Therapeutics Inc. (BCLI) recorded performance in the market was -51.25%, having the revenues showcasing -53.01% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 71.76M, as it employees total of 43 workers.

Brainstorm Cell Therapeutics Inc. (BCLI) in the eye of market guru’s

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 3.2525, with a change in the price was noted -0.80. In a similar fashion, Brainstorm Cell Therapeutics Inc. posted a movement of -29.09% for the period of last 100 days, recording 229,015 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BCLI is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Brainstorm Cell Therapeutics Inc. (BCLI): Stocks Technical analysis and Trends

Raw Stochastic average of Brainstorm Cell Therapeutics Inc. in the period of last 50 days is set at 24.88%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 33.58%. In the last 20 days, the company’s Stochastic %K was 22.32% and its Stochastic %D was recorded 19.56%.

If we look into the earlier routines of Brainstorm Cell Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -51.25%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -32.53%, alongside a downfall of -30.60% for the period of the last 12 months. The shares increased approximately by 12.72% in the 7-day charts and went up by -42.31% in the period of the last 30 days. Common stock shares were lifted by -53.01% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts